By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo

TheMediTary.Com

Medical Information, Documents, News - TheMediTary.Com

  • Home
  • News
  • Drugs
  • Drugs A-Z
  • Medical Answers
  • About Us
  • Contact
Medical Information, Documents, News - TheMediTary.Com Logo Medical Information, Documents, News - TheMediTary.Com Logo
Search Drugs
  • Drugs
    • Latest Drugs
    • Drugs A-Z
    • Medical Answers
  • News
    • FDA Alerts
    • Medical News
    • Health
    • Consumer Updates
    • Children's Health
  • More TheMediTary.Com
    • About Us
    • Contact
Follow US
Home > Drugs > Anticholinergic bronchodilators > Glycopyrrolate (inhalation) > Glycopyrrolate Dosage
Anticholinergic bronchodilators
https://themeditary.com/dosage-information/glycopyrrolate-dosage-10307.html

Glycopyrrolate Dosage

Drug Detail:Glycopyrrolate (inhalation) (Glycopyrrolate (inhalation) [ glye-koe-pir-oh-late ])

Drug Class: Anticholinergic bronchodilators Anticholinergics / antispasmodics

Contents
Uses Warnings Before Taking Dosage Side effects Interactions

Usual Adult Dose for Anesthesia

Preanesthetic: 0.004 mg/kg intramuscularly 30 to 60 minutes prior to anticipated induction of anesthesia.

Intraoperative: 0.1 mg intravenously; repeat every 2 to 3 minutes as needed

  • Use to counteract drug-induced or vagal reflexes associated with arrhythmias (e.g. bradycardia)
  • The usual attempts should be made to determine the cause of cardiac arrhythmias; perform surgical or anesthetic manipulations needed to correct parasympathetic imbalance.

Neuromuscular blockage reversal: 0.2 mg for each 1.0 mg neostigmine or 5.0 mg pyridostigmine
  • Drugs may be administered together (simultaneous intravenous injection or mixed in the same syringe) to minimize appearance of cardiac effects.

Comments:
  • The injectable product contains benzoyl alcohol.

Uses: During anesthesia induction and intubation, to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions, and to block cardiac vagal inhibitory reflexes

Usual Adult Dose for Peptic Ulcer

Oral tablets:
1 mg oral tablets: 1 mg orally 3 times a day (morning, afternoon, and bedtime)

  • Some patients will require 2 mg at bedtime to assure overnight symptom control
2 mg oral tablets: 2 mg orally twice to 3 times a day at equally spaced intervals
Maximum dose: 8 mg daily
  • Titrate dose based on response and adverse effects


Injection solution:
0.1 mg intramuscularly or intravenously every 4 hours three or four times a day
  • May use 0.2 mg if a more profound effect is required.
Maximum dose: 4 doses per day
  • Some patients may need only a single dose; base frequency of administration on patient response.


Comments:
  • The injectable product contains benzoyl alcohol.

Uses: Adjunctive treatment of peptic ulcer

Usual Adult Dose for Chronic Obstructive Pulmonary Disease - Maintenance

Solution for inhalation: Inhale contents of one vial twice a day using accompanying nebulization system

Capsules for inhalation: Inhale contents of one capsule twice a day using accompanying inhaler

Comments:

  • For inhalation only - do not swallow.
  • Administer at the same time of day.
  • More frequent administration or higher doses are not recommended.

Use: Long term maintenance treatment of airflow obstruction in chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema

Usual Pediatric Dose for Anesthesia

Preanesthetic: 0.004 mg/kg intramuscularly 30 to 60 minutes prior to anticipated induction of anesthesia.

  • Infants (1 month to 2 years) may require up to 0.009 mg/kg

Intraoperative: 0.004 mg intravenously; repeat every 2 to 3 minutes as needed
Maximum dose: 0.1 mg per single dose
  • Because of its long half-life, additional doses are rarely needed
  • Use to counteract drug-induced or vagal reflexes associated with arrhythmias (e.g. bradycardia)
  • The usual attempts should be made to determine the cause of cardiac arrhythmias; perform surgical or anesthetic manipulations needed to correct parasympathetic imbalance.

Neuromuscular blockage reversal: 0.2 mg for each 1.0 mg neostigmine or 5.0 mg pyridostigmine
  • Drugs may be administered together (simultaneous intravenous injection or mixed in the same syringe) to minimize appearance of cardiac effects.

Comments:
  • The injectable product contains benzoyl alcohol.

Uses: During anesthesia induction and intubation, to reduce salivary, tracheobronchial, and pharyngeal secretions, to reduce the volume and free acidity of gastric secretions, and to block cardiac vagal inhibitory reflexes

Usual Pediatric Dose for Excessive Salivation

1 mg/5 mL oral liquid, children 3 to 16 years:
Initial dose: 0.02 mg/kg orally 3 times a day, at least one hour before or 2 hours after meals

  • Titrate in increments of 0.02 mg/kg every 5 to 7 days, based on response and adverse effects
Maximum dose: 0.1 mg/kg 3 times a day, not to exceed 1.5 to 3 mg per dose based on weight

Use: To reduce chronic severe drooling in patients aged 3 to 16 years with conditions associated with problem drooling (e.g. cerebral palsy)

Renal Dose Adjustments

Dose adjustment(s) may be required; however, no specific guidelines have been suggested. Caution is recommended. (intravenous solution)
No adjustment recommended for mild to moderate renal impairment (inhalation powder/solution)
Use with caution (oral tablets)

  • Renal elimination may be severely impaired in renal failure.

Liver Dose Adjustments

No adjustment recommended (inhalation powder)
Use with caution (oral tablets)

Precautions

  • Hypersensitivity to any of the ingredients
  • In managing peptic ulcer, because of the longer duration of therapy, may be contraindicated in: glaucoma, obstructive uropathy (e.g. bladder neck obstruction due to prostatic hypertrophy), obstructive gastrointestinal disease (e.g. achalasia, pyloroduodenal stenosis), paralytic ileus, intestinal atony of the elderly or debilitated, unstable cardiovascular status in acute hemorrhage, severe ulcerative colitis, toxic megacolon complicating ulcerative colitis, myasthenia gravis

Safety and efficacy of the inhalation powder have not been established in patients younger than 18 years.

Safety and efficacy of the oral tablets have not been established in patients younger than 12 years.

Safety and efficacy of the oral liquid have not been established in patients younger than 3 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

IV compatibility:

  • Compatible with: Dextrose 5% and 10%, saline, dextrose 5% in sodium chloride 0.45%, sodium chloride 0.9%, and Ringer's Injection
  • Incompatible with: Lactated Ringer's solution

Patient advice:
  • This drug may cause blurred vision or drowsiness; do not engage in activities requiring mental alertness and/or visual acuity such as operating machinery or a motor vehicle, or when performing hazardous tasks.
Share this Article
Latest News
Medical News

Shingles vaccine may lower heart disease risk by up to 8 years

May 09, 2025
Obesity, unhealthy lifestyles may cause heart to age by 5–45 years
Aging: As little as 5 minutes of exercise may keep the brain healthy
Prostate cancer: Simple urine test may help with early detection
Cancer treatment side effects: Exercise may reduce pain, fatigue
Alzheimer's: Exercising in middle age may reduce beta-amyloid in brain...
Related Drugs
Fidanacogene Elaparvovec
Cerave Anti-Itch
Centrum Adult
Crovalimab
Cyltezo Prefilled Syringe
Zepbound Pen
Mylanta One
Uretron Ds
Medihoney Wound And Burn Dressing
Lidotrode

Other drugs

Name Drug Class Updated
Fidanacogene Elaparvovec Drugs 03-Oct-2024
Cerave Anti-Itch Drugs 02-Oct-2024
Centrum Adult Drugs 02-Oct-2024
Crovalimab Drugs 02-Oct-2024
Cyltezo Prefilled Syringe Drugs 01-Oct-2024
Zepbound Pen Drugs 30-Sep-2024
Mylanta One Drugs 27-Sep-2024
Uretron Ds Drugs 27-Sep-2024
Medihoney Wound And Burn Dressing Drugs 26-Sep-2024
Lidotrode Drugs 26-Sep-2024
Libervant Drugs 26-Sep-2024
Moderna Covid-19 Drugs 25-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024
Beqvez Drugs 24-Sep-2024

Categories

  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health

About US

Welcome to TheMediTary.Com

Our website provides reliable and up-to-date information on various medical topics. We empower individuals to take charge of their health by simplifying complex medical jargon and providing practical tips and advice. We prioritize the privacy and confidentiality of our users and welcome feedback to improve our services.

Website use data of FDA and other sources

DMCA.com Protection Status Truste Protection Status Trust Mark Protection Status
HONcode logo We comply with the HONcode standard for trustworthy health information.
Quick Link
  • About Us
  • Contact Us
  • Editorial Policy
  • Privacy Policy
  • Accessibility Policy
  • Terms & Conditions
  • Disclaimer
  • DMCA
  • Do Not Sell My Personal Information
  • Sitemap
  • Care Notes
  • Health Guide
  • Professional
Drugs
  • New Drugs
  • Medical Answers
  • Drugs A-Z
  • Drug Classes
  • Drug Dosage
  • Pill Identifier
  • Consumer Infor
  • Side Effects
  • Inactive Ingredients
  • Pregnancy Warnings
  • Patient Tips
  • Treatments
News
  • Latest News
  • FDA Alerts
  • Medical News
  • Health
  • Consumer Updates
  • Children's Health
Find US
  • Medium
  • Google Site
  • Blogspot
  • API
  • Reddit
  • Tumblr
  • Scoop.it
  • Substack
  • Wordpress
  • Wix
  • Behance

© 2025 TheMediTary.Com All rights reserved. Operated by